Clinical Trial Update: Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating adding Peposertib (M3814) to radiotherapy for locally advanced pancreatic cancer is currently recruiting (Phase 1/2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• Peposertib (M3814) (peposertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8 | Phase 1, Phase 2 | Status: RECRUITING